Introduction
============

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease with significant extrapulmonary effects that may contribute to the severity in individual patients. By 2030, COPD will be the fourth cause of mortality worldwide. The extrapulmonary comorbidities influence the prognosis of the patients with COPD ([@ref-15]).

Metabolic syndrome (MS) is common in patients with COPD. According to the available studies the prevalence of MS in COPD patients varies between 21--53% ([@ref-24]). The prevalence of MS in COPD patients is increased when compared to a control group ([@ref-13]; [@ref-18]; [@ref-21]; [@ref-31]).

Available studies suggest that MS may have impact on quality of life ([@ref-12]), lung function ([@ref-11]; [@ref-19]; [@ref-20]; [@ref-28]; [@ref-43]), natural course of COPD (number of exacerbations) ([@ref-17]; [@ref-1]) as well as to affect comorbidities in COPD patients ([@ref-25]).

Many studies examine prevalence of MS in COPD patients ([@ref-13]; [@ref-18]; [@ref-31]; [@ref-17]; [@ref-2]; [@ref-22]; [@ref-27]; [@ref-30]; [@ref-35]; [@ref-40]) with results being highly variable between studies. The prevalence of MS in an unselected Bulgarian population aged 20--80 years is 30.8%. The prevalence of MS for participants over 45 years (the most common age group for the COPD patients) is higher, 44.6% ([@ref-6]). An epidemiological study conducted in Bulgaria in 3,598 COPD patients showed that metabolic syndrome is found in 13.8% of the patients ([@ref-33]). A more recent study indicates that the prevalence of metabolic syndrome is 41.8% in 141 patients with COPD compared to 39% in the control group of 103 subjects ([@ref-38]). The prevalence of MS in COPD patients, hospitalized for exacerbation is hard to predict because MS tends to be more prevalent in early stages of COPD while patients experiencing severe exacerbation often have advanced disease. On the other side, MS may impact natural course of COPD and predispose to exacerbation which will lead to increased prevalence of MS in this group.

There is not enough data to determine whether the results from these studies are applicable to specific subgroups of patients, such as COPD patients admitted for exacerbation. COPD is increasingly divided in subgroups or phenotypes based on specific features and association with prognosis or response to therapy, the most notable being the feature of frequent exacerbations ([@ref-39]). The presence of MS may also have distinctive characteristics for this subgroup ('severe' exacerbator phenotype). The aim of this study is to find out the prevalence of MS in patients with COPD admitted for exacerbation and the correlations of presence of MS with comorbidities and COPD characteristics.

Material and Methods
====================

A total of 152 COPD patients hospitalized for exacerbation were studied for the presence of MS, DM, and vitamin D deficiency and insufficiency using well-established criteria for:

1.  Presence of MS: at least 3 of the following: 1. Elevated waist circumference \>102 cm in males, \>88 cm in females; 2. Triglycerides \>1.7 mmol/L (or on therapy); 3. HDL \<1.0 mmol/L in males, \<1.3 mmol/L in females (or on therapy); 4. Elevated blood pressure: systolic ≥130 and/or diastolic ≥85 mm Hg (or on therapy); 5. Fasting glucose \>5.5 mmol/L (or on therapy) ([@ref-3]).

2.  Presence of DM: fasting plasma glucose ≥7.0 mmol/L OR 2-h plasma glucose ≥11.1 mmol/L during an oral glucose tolerance test (OGTT) OR HbA1c≥6.5% OR on therapy ([@ref-4]);

3.  Presence of prediabetes: fasting plasma glucose 5.6--6.9 mmol/L OR 2-h plasma glucose 7.8--11.0 mmol/L during an OGTT OR HbA1c 5.7--6.4% ([@ref-4]);

4.  Presence of vitamin D deficiency: 25(OH)D \<25 nmol/L; vitamin D insufficiency: 25(OH)D 25--50 nmol/L; vitamin D sufficiency: \>50 nmol/L ([@ref-7]).

The diagnosis of COPD was made according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria (DM1). Data were gathered for age, sex, smoking status and number of pack-years, number of bone fractures, therapy for arterial hypertension, therapy for DM, COPD therapy and number of exacerbations in the last year. The patients completed CAT and mMRC questionnaires and underwent pre- and post bronchodilatatory spirometry. Blood pressure was obtained according to the American Heart Association Guidelines ([@ref-34]). A patient was considered as having arterial hypertension if taking antihypertensives.

The inclusion criteria were post bronchodilator spirometry obstruction defined as FEV1/FVC\<0.70. All participants in this study signed informed consent.

The exclusion criteria were failure to comply with study procedures (no completed questionnaires, no medical and demographic information, no spirometry, no lab tests) or FEV1/FVC ratio \>0.70 after administration of bronchodilator.

Smoking status
--------------

Every participant was classified according to smoking status ([@ref-37]):

Never smoker---never smoked a cigarette or who smoked fewer than 100 cigarettes in their entire lifetime.

Former smoker---smoked at least 100 cigarettes in their entire life but were not currently smoking.

Current smoker---had smoked at least 100 cigarettes in their entire life and were still smoking.
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}{}\begin{eqnarray*} \text{Number of pack-years}=\text{years of smoking}\times \text{number of daily smoked cigarettes/20}. \end{eqnarray*}\end{document}$$

Anthropometric indices
----------------------

Body weight and height were measured and the body mass index (BMI) was calculated by dividing weight by height squared (kg/m^2^). According to BMI all patients were classified as underweight (\<18.5), normal (18.5--24.99), overweight (25--29.99) and obese (\>30). Waist circumference was measured at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest according to the WHO STEPS protocol ([@ref-41]). Hip circumference was measured around the widest portion of the buttocks ([@ref-41]). Body adiposity index (BAI) was calculated as: $$\documentclass[12pt]{minimal}
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COPD exacerbations and duration of hospital stay
------------------------------------------------

Data were gathered for number of severe exacerbations (hospitalizations) and moderate exacerbations (antibiotic or/and systemic steroid treatment without hospitalization due to worsening of pulmonary symptoms) ([@ref-15]) in the previous year. The duration of the current hospital stay was recorded.

Quality of life
---------------

Quality of life was assessed with the mMRC scale and CAT questionnaire. Patients were instructed that there were no right or wrong answers. All patients' questions were answered. Patients were classified according to GOLD as having less symptoms (CAT \< 10) and breathlessness (mMRC grade 0--1) and more symptoms (CAT ≥ 10) and breathlessness (mMRC grade ≥ 2). Because all patients were hospitalized due to exacerbation there were only group C (high risk, less symptoms) and group D (high risk, more symptoms) patients according to GOLD ([@ref-15]).

Pulmonary function testing
--------------------------

The spirometry was performed using Minispir^®^ New spirometer (MIR---Medical International Research, Rome, Italy). Patients were instructed to withdraw using short-acting *β*2-agonists at least 6 h, long-acting *β*2-agonist at least 12 h, long acting muscarinic antagonist 24 h and short acting muscarinic antagonist 12 h before the spirometry ([@ref-26]). Post bronchodilator spirometry testing was performed 15--30 min after inhalation of 400mcg Salbutamol according to ERS/ATS recommendations ([@ref-26]). Pre- and post- values were obtained for: FVC, FEV1, FEV1/FVC, FEV6, FEV1/FEV6, PEF, FEF2575, FEV3, FEV3/FVC as well as the difference between post/pre values (delta values). GLI (Global Lungs Initiative) predicted values were used (GLI-2012). Patient's obstruction was classified according to the severity of airflow limitation based on post-bronchodilator FEV1 as follows: mild (≥80% predicted); moderate (80\>FEV1 ≥ 50% predicted); severe (50%\>FEV1≥30% predicted); very severe (\<30% predicted) ([@ref-15]).

Blood samples and analyses
--------------------------

A venous blood sample was collected from each subject after a 12-h fasting. Blood samples were taken as late as possible before discharging (usually on 6th or 7th day). Plasma glucose, triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), and total cholesterol (tChol) were measured with a Roche COBAS INTEGRA^®^ 400 plus analyzer and an enzymatic colorimetric assay and blood glucose was measured with an enzymatic reference method with hexokinase. Vitamin D was measured with Elecsys 2010 (Roche, Basel, Switzerland) and Electro-chemiluminescence immunoassay (ECLIA). Glycated hemoglobin (HbA1c) was measured with a NycoCard device and boronate affinity assay. For patients without established DM a 75 g OGTT was performed with blood samples for glucose taken on first and second hour.

Statistical analysis
--------------------

Statistical analysis was performed with the SPSS for Windows software, version 22.0 (SPSS Inc., Chicago, Illinois, USA). Continuous variables were presented as mean ± standard deviation and 95 Confidence intervals (95%CI) and categorical variables---as percentages. Chi-square test was used to determine the associations between categorical variables. Continuous variables were examined for normality by Shapiro--Wilk test. For normally distributed variables, differences between the groups were determined by independent-samples *T* test for two samples and analysis of variance (ANOVA) for more than 2 samples. Mann--Whitney U test was used for abnormally distributed variables with 2 samples and Kruskal-Wallis test for variables with more than 2 samples. Regression analyses were used to determine risk factors for presence of MS or the consequences of having MS. Significance value (*p*-value) was set at 0.05.

All patients signed informed consent. Medical University-Sofia Research Ethics Commission approved the study (\#2976/2014).

Results
=======

Sample characteristics
----------------------

A total of 152 COPD patients admitted for exacerbation were recruited from University Specialized Hospital for Active Treatment of Pulmonary Diseases 'Saint Sofia,' Sofia, Bulgaria. Mean age of patients in this study was 65 ± 10 years. 71.1% (108/152) were males, 28.9% (44/152) were females; mean post-bronchodilator FEV~1~ was 55.3 ± 19.5%. 15.8% from the patients were never smokers, 57.9%---former smokers and 26.3%---current smokers. 127 patients (83.6%) were receiving inhalatory corticosteroids.

Prevalence of MS
----------------

25.0% (38/152) of the patients have MS. 23.1% (25/108) of males have MS vs. 29.5% (13/44) of females but this difference is not statistically significant ([Table 1](#table-1){ref-type="table"}). Mean age does not differ between the patients with and without MS.
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###### Prevalence of MS according to different factors.
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                              \% MS   *P* value
  --------------------------- ------- ---------------------
  **Sex**                             
  Male                        23.1    *P* = 0.409
  Female                      29.5    
  **Smoking status**                  
  Never                       25.0    *P* = 0.678
  Former                      27.3    
  Current                     20.0    
  **ICS use**                         
  Yes                         25.2    *P* = 0.899
  No                          24.0    
  **Arterial hypertension**           
  Yes                         35.2    ***P*\<0.0005**
  No                          2.1     
  **Vitamin D status**                
  \>50 nmol/l                 24.2    *P* = 0.929
  25--50 nmol/l               24.6    
  \<25 nmol/l                 28.0    
  **DM**                              
  Yes                         37.7    ***P*=0.008**
  No                          18.2    
  **BMI**                             
  Underweight                 0       ***P*\<0.0005**
  Normal                      0       
  Overweight                  27.3    
  Obese                       54.8    
  **BAI**                             
  Underweight                 0       ***P* = **0.001****
  Normal                      17.5    
  Overweight                  28.9    
  Obese                       50.0    
  **Quality of life**                 
  CAT 0--9                    16.0    ***P* = **0.256****
  CAT ≥ 10                    26.8    
  mMRC 0 or 1                 18.9    ***P***= **0.201**
  mMRC ≥ 2                    28.3    
  **FEV1**                            
  FEV1≥50%                    21.3    *P* = 0.390
  FEV1\<50%                   27.5    
  FEV1≥80%                    11.8    *P* = 0.852
  80%\>FEV1≥50%               28.8    
  50%\>FEV1≥30%               26.1    
  FEV1\<30%                   25.0    

Fulfilled criteria for MS (in all and in MS patients) are shown in [Table 2](#table-2){ref-type="table"}. Virtually all (37/38) patients with MS in this study have arterial hypertension, followed by elevated waist circumference (33/38). Arterial hypertension has greatest sensitivity for predicting presence of MS, but is not specific. Elevated waist circumference has greatest accuracy, defined as sum of true results (true positives and true negatives) divided by total number of cases. Number of fulfilled criteria in all patients is given in [Table 3](#table-3){ref-type="table"}.
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###### Fulfilled criteria for MS.
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  MS criteria                                                                         All patients (*n* = 152)   MS only (*n* = 38)   Without MS (*n* = 114)   Accuracy
  ----------------------------------------------------------------------------------- -------------------------- -------------------- ------------------------ ----------
  Elevated blood pressure: systolic ≥130 and/or diastolic ≥85 mm Hg (or on therapy)   69.1% (*n* = 105)          97.4% (*n* = 37)     59.6% (*n* = 68)         54.6%
  Elevated waist circumference \>102 cm in males, \>88 cm in females                  28.3% (*n* = 43)           86.8% (*n* = 33)     8.8% (*n* = 10)          90.1%
  Triglycerides \>1.7 mmol/L (or on therapy)                                          29.6% (*n* = 45)           60.5% (*n* = 23)     19.3% (*n* = 22)         75.7%
  Fasting glucose \>5,5 mmol/L (or on therapy)                                        34.2% (*n* = 52)           65.8% (*n* = 25)     23.7% (*n* = 27)         73.7%
  HDL \<1.0 mmol/L in males, \<1.3 mmol/L in females (or on therapy)                  15.8% (*n* = 24)           39.5% (*n* = 15)     7.9% (*n* = 9)           78.9%
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###### Number of fulfilled criteria for MS in all patients.
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  Number of fulfilled criteria   \%     *n*
  ------------------------------ ------ -----
  0                              13.8   21
  1                              33.6   51
  2                              27.6   42
  3                              13.2   20
  4                              10.5   16
  5                              1.3    2

Lifestyle factors
-----------------

Our study did not find significant differences in prevalence of MS according to smoking status and number of pack-years. Treatment with inhalatory corticosteroids (ICS) is not risk factor for MS. Fasting glucose level are not influenced by ICS (all *p* \> 0.05) ([Table 1](#table-1){ref-type="table"}).

Comorbidity
-----------

In our study, vitamin D levels do not significantly differ in relation to presence of MS (32.11 vs. 31.92 nmol/l). The presence of MS is also not related to vitamin D status ([Table 1](#table-1){ref-type="table"}).

Number of fractures in our study does not significantly differ regarding the presence of MS. Presence of at least one fracture also does not differ significantly in relation to presence of MS.

In our study there is a correlation between the presence of MS and DM. 52.6% (20/38) from patients with MS have DM. BMI and BAI differ significantly according to presence of MS---32.51 vs. 25.58, for BMI and 31.01 vs. 25.58, for BAI. There is also significant difference in prevalence of MS in BMI and BAI groups ([Table 1](#table-1){ref-type="table"}). It is notable that none of the patients have MS and BMI \< 25 ([Table 1](#table-1){ref-type="table"}).

Linear regression showed presence of MS as risk factor for higher BMI (*R* = 0.542, *r*^2^ = 0.293, *p* \< 0.0005, B = 6.928, 95% CI \[5.193--8.662\]) and BAI (*R* = 0.406, *r*^2^ = 0.165, *p* \< 0.0005, B = 5.423, 95% CI \[3.455--7.392\]).

A logistic regression analysis was conducted to predict presence of MS in a relation to presence of other comorbidities. Presence of DM slightly improves the model (chi square = 6.818, *p* = 0.009 with *df* = 1). Nagelkerke's R2 of 0.065 indicates a weak relationship. Odds ratio was 2.73. Vitamin D status does not improve the model (*p* \> 0.05).

Exacerbations and duration of hospital stay
-------------------------------------------

Our study found a significant difference between the number of total exacerbations according to the presence of MS ([Table 4](#table-4){ref-type="table"}, *p* = 0.015). The number of severe exacerbation, moderate exacerbation and duration of hospital stay did not reach significance.
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###### Number of exacerbations in previous year and duration of hospital stay.
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                            No MS                   MS
  ------------------------- ----------------------- -----------------------
  Moderate exacerbations    0,61 (0,49--0,76)       0,92 (0,59--1,34)
  Severe exacerbations      1,79 (1,61--1,97)       2,08 (1,71--2,50)
  All exacerbations         **2,40 (2,19--2,61)**   **3,00 (2,56--3,52)**
  Hospital stay (in days)   7,47 (7,24--7,70)       7,63 (7,28--8,05)

Triglycerides and blood glucose levels in our study did not correlate with number of exacerbations.

Linear regression showed presence of MS as risk factor for higher number of exacerbations (*R* = 0.207, *r*^2^ = 0.043, *p* = 0.010, B = 0.596, 95% CI \[0.143--1.050\]). From the MS components presence of arterial hypertension is strongest risk factor for exacerbation (R = 0.228, *r*^2^ = 0.052, *p* = 0.005, *B* = 0.615, 95% CI \[0.192--1.038\]).

Quality of life
---------------

The presence of MS is associated with significantly worse cough and sleep (1st and 7th CAT questions; *p* = 0.002 and *p* = 0.001 respectively) and higher total CAT score (*p* = 0.017) ([Table 5](#table-5){ref-type="table"}). However prevalence of MS is not significantly different between patients with less symptoms (CAT 0--9) and breathlessness (mMRC 0 or 1) compared to patients with more symptoms (CAT ≥ 10) and breathlessness (mMRC ≥ 2) ([Table 1](#table-1){ref-type="table"}).
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###### Mean CAT score on every question and in total according to presence of MS.
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  MS         Mean CAT score    N     *P* value
  ---------- ----------------- ----- -----------------
  MS---no    CAT1 1.95         114   ***P*=0.002**
  MS---yes   CAT1 2.63         38    
  MS---no    CAT2 1.92         114   *P* = 0.063
  MS---yes   CAT2 2.34         38    
  MS---no    CAT3 2.54         114   *P* = 0.092
  MS---yes   CAT3 2.97         38    
  MS---no    CAT4 3.52         114   *P* = 0.361
  MS---yes   CAT4 3.74         38    
  MS---no    CAT5 1.23         114   *P* = 0.198
  MS---yes   CAT5 1.66         38    
  MS---no    CAT6 1.54         114   *P* = 0.695
  MS---yes   CAT6 1.68         38    
  MS---no    CAT7 1.28         114   ***P*=0.001**
  MS---yes   CAT7 2.21         38    
  MS---no    CAT8 2.62         114   *P* = 0.068
  MS---yes   CAT8 3.08         38    
  MS---no    Total CAT 16.61   114   ***P* = 0.017**
  MS---yes   Total CAT 20.32   38    

Regression analyses also showed that MS is a risk factor for reduced quality of life, measured with total CAT score (*R* = 0.205, *r*^2^ = 0.042, *p* = 0.011, *B* = 3.711, 95% CI \[0.859--6.562\]). Presence of MS also impairs cough and sleep---first (R = 0.285, *r*^2^ = 0.081, *p* \< 0.0005, *B* = 0.684, 95% CI \[0.313--1.055\]) and seventh (*R* = 0.268, *r*^2^ = 0.072, *p* = 0.001, *B* = 0.930, 95% CI \[0.390--1.470\]) CAT questions.

Pulmonary function test (PFT)
-----------------------------

Our study did not find differences in FVC, FEV1, FEV1/FVC, FEV6, FEV1/FEV6, PEF, FEF2575 and FEV3 according to the presence of MS. It should be noted that there is tendency for FVC and FEV1/FVC ratio. However, because of this there is significant difference in FEV3/FVC ratio ([Table 6](#table-6){ref-type="table"}).
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###### Mean PFT values.
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  MS    Mean PFT value   N     *P* value
  ----- ---------------- ----- --------------------
  No    FEV1 55.56%      114   *P* = 0.811
  Yes   FEV1 54.68%      38    
  No    FVC 80.46%       114   *P* = 0.094
  Yes   FVC 72.45%       38    
  No    FEV1/FVC 0.53    114   *P* = 0.091
  Yes   FEV1/FVC 0.57    38    
  No    FEV6 73.89%      114   *P* = 0.277
  Yes   FEV6 68.63%      38    
  No    FEV1/FEV6 0.57   114   *P* = 0.107
  Yes   FEV1/FEV6 0.61   38    
  No    PEF 55.62%       114   *P* = 0.735
  Yes   PEF 56.66%       38    
  No    FEF2575 38.89%   114   *P* = 0.316
  Yes   FEF2575 40.95%   38    
  No    FEV3 66.62%      114   *P* = 0.601
  Yes   FEV3 63.89%      38    
  No    FEV3/FVC 0.81    114   ***P* =**0.033****
  Yes   FEV3/FVC 0.85    38    

Regression analyses also showed that MS is not a risk factor for reduced pulmonary function. However some of the components of MS are associated with reduced pulmonary function with highest impact of HDL on FVC (*R* = 0.183, *r*^2^ = 0.033, *p* = 0.024, *B* = − 8.517, 95% CI \[−15.904--−1.130\]) and FEV1 (*R* = 0.251, *r*^2^ = 0.063, *p* = 0.001, *B* = − 10.391, 95% CI \[−16.865--−3.918\]). Fasting glucose is associated with increased FEV1/FVC ratio (*R* = 0.186, *r*^2^ =0.035, *p* = 0.022, *B* = 1.238, 95% CI \[0.183--2.294\]) probably because of lowering FVC.

There is no difference in prevalence of MS in patients with FEV1 \<50%, when compared to patients with FEV1 \>50% or regarding GOLD stage ([Table 1](#table-1){ref-type="table"}).

Discussion
==========

This study found comparable but relatively low prevalence of MS compared to previous studies ([Table 7](#table-7){ref-type="table"}) ([Fig. 1](#fig-1){ref-type="fig"}). The prevalence of MS in our study is significantly lower when compared to the general Bulgarian population (44.6% in subjects over 45 years) ([@ref-6]). The odds ratio for COPD patients admitted for exacerbation of having MS is 0.41 compared to general population (95% CI \[0.28--0.61\], *p* \< 0.0005).

![Prevalence of MS in COPD patients.](peerj-03-1068-g001){#fig-1}
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###### Prevalence of MS in patients with COPD.
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  Authors     *N*     Studied population                           Prevalence of MS
  ----------- ------- -------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  [@ref-2]    133     Patients with COPD and controls              **44.6%**
  [@ref-13]   7.189   Men aged 45--88 years                        **16.8%**, OR 0.72 (95% CI \[0.51--1.02\]) in GOLD I; **28.7%**, OR 1.33 (95% CI \[1.01--1.76\]) in GOLD II--IV
  [@ref-17]   106     Hospitalized patients with COPD              **27.3%**
  [@ref-18]   7.358   General population \>50 years                **22.6%**; OR 1.47 (95% CI \[1.12--1.92\])
  [@ref-22]   72      Patients with COPD and controls              **47%**
  [@ref-27]   114     Men with COPD                                **21%**
  [@ref-30]   90      Patients with COPD and controls              **43%**
  [@ref-31]   1.215   Patients with COPD and controls \>40 years   **33%** vs. 22.2% for men; **48.5%** vs. 29.6% for women OR 2.03 (95% CI \[1.08--3.80\])
  [@ref-35]   28      Patients with COPD                           Overweight---**50%**; Normal weight---**0%**.
  [@ref-40]   200     Patients with COPD and chronic bronchitis    GOLD I---**50%**; GOLD II---**53%**; GOLD III---**37%**; GOLD IV---**44%**; Chronic bronchitis---53%

Two Bulgarian studies examined the prevalence of MS in COPD patients. An epidemiological study conducted in Bulgaria in COPD patients reported a prevalence of 13.8%. These results differ significantly from the literature data probably because of the different criteria for metabolic syndrome (presence of DM, BMI \>30 and blood pressure \>140/90 mmHg) which makes data comparing irrelevant ([@ref-33]). A more recent study indicates that the prevalence of metabolic syndrome is 41.8% in patients with COPD . However, this study was not conducted using a random sample (exclusion criteria was presence of DM, people were aged 49--79 years for patients with COPD and 35--65 years for controls) ([@ref-38]). Nonetheless it uses similar criteria for MS and when comparing the results our study finds lower prevalence of MS.

The prevalence results could be explained with differences between the populations in different studies (physical activity, diet, lifestyle etc.). For example, Bulgaria is low-income country, which may impact diet preferences and treatment choices. Furthermore, patients in this study had been hospitalized due to exacerbation, which represents the most severe group of COPD patients. Having in mind that MS is more common in the early stages and decreases with COPD progression ([@ref-40]), COPD patients hospitalized for exacerbation may be considered as having advanced COPD.

According to the NHANES III study, smokers are more likely to develop MS than nonsmokers in general population, and the risk increases with the number of pack-years even after adjusting for covariates ([@ref-32]). Our study did not find significant differences in prevalence of MS according to smoking status and number of pack-years. These results could be explained with smoke being the biggest factor in developing COPD and effect of developing MS could be reduced. Moreover nicotine may be an appetite suppressant and lower the weight thus decreasing prevalence of metabolic syndrome ([@ref-10]). Third, hospitalized COPD patients are patients with predominantly advanced disease and prone to cachexia and wasting. Also, lifestyle changes (quiting smoking) in the presence of the two diseases should be considered which may change the prevalence of MS.

Treatment with inhalatory corticosteroids (ICS) is not risk factor for MS similar to findings for DM ([@ref-29]) and fasting glucose level are not influenced by ICS.

COPD is a disease that affects mainly the lungs, but is characterized by systemic inflammation and a number of extrapulmonary manifestations. Only 1/3 of patients with COPD die due to respiratory failure. Main cause of death is lung cancer and cardiovascular complications ([@ref-9]).

The vast majority of patients with COPD have a vitamin D deficiency ([@ref-36]). Aside from its role in the metabolism of calcium and phosphorus, vitamin D is involved in the pathogenesis of multiple diseases, including MS, mainly because it affects the secretion and the function of insulin ([@ref-16]). However, in our study vitamin D levels do not significantly differ in relation to presence of MS. Presence of MS is also not related to vitamin D status.

There are no studies that examine the relationship between osteoporosis and MS in patients with COPD. However, both diseases share common risk factors such as smoking, lack of physical activity, and treatment with corticosteroids. Some of the components of the metabolic syndrome (arterial hypertension, elevated triglycerides, reduced HDL cholesterol) are risk factors for low bone density. Systemic inflammation in MS plays a role in the pathogenesis of osteoporosis ([@ref-23]). On the other hand, studies examining the relationship between MS and osteoporosis showed inconsistent results, probably due to the protective effect of obesity ([@ref-44]). However, the number of fractures in our study does not significantly differ regarding the presence of MS. The presence of at least one fracture also does not differ significantly in relation to presence of MS.

Most patients with DM have MS, but the opposite is not necessarily true ([@ref-14]). The presence of MS in this study is associated with presence of DM, higher BMI and BAI.

Hyperglycemia is associated with elevated glucose concentrations in tissues and bronchial aspirates where it may stimulate infection by enhancing bacterial growth and by promoting bacterial interaction with the airway epithelium ([@ref-8]). Hyperglycemia also impairs both innate and adaptive immunity, suppressing the host response to infection.

The presence of MS in patients with COPD increases the frequency of exacerbations (2.4 vs. 0.7) and their duration--(7.5 vs. 5.0 days) according to [@ref-17], and 8 versus 5.5 days, according to [@ref-1]. Our study found a significant difference between the number of total exacerbations according to the presence of MS. However, the number of severe exacerbation, moderate exacerbation and duration of hospital stay did not differ significantly. Triglycerides and blood glucose levels in our study did not correlate with number of exacerbations as reported by other authors ([@ref-17]).

The presence of MS is associated with significantly worse cough and sleep and higher total CAT score. This confirms the data about reduced quality of life in patients with MS ([@ref-12]). However, the prevalence of MS is not significantly different between patients with less symptoms (CAT 0--9) and breathlessness (mMRC 0 or 1) compared to patients with more symptoms (CAT ≥10) and breathlessness (mMRC ≥2). These mixed results may be explained with COPD having higher negative impact on quality of life than MS (physical limitation due to shortness of breath) as suggested for DM ([@ref-5]), and ameliorating the effect in patients having both diseases.

COPD is characterized by airflow obstruction, which is not fully reversible. MS is associated with a reduction of lung volumes ([@ref-11]; [@ref-19]; [@ref-20]; [@ref-28]; [@ref-43]). It should be noted that some studies found no association between lung function and the presence of MS ([@ref-42]). MS in our study is not associated with worsen pulmonary function. There is also no difference in prevalence of MS in patients with FEV1 \<50%, when compared to patients with FEV1 \>50% or regarding GOLD stage.

Conclusions
===========

This study finds a 25% prevalence of MS in COPD patients admitted for exacerbation, which is significantly lower than the general population. MS is more prevalent in females, but the gender difference is not statistically significant. In this study, most of the patients are former smokers, and the prevalence of MS does not differ regarding smoking status and treatment with ICS.

The presence of MS is associated with the presence of DM, higher BMI and BAI, more exacerbations during the previous year and lower quality of life. MS is not associated with increased hospital stay and lower pulmonary function.

This study finds comparable but relatively low prevalence of MS compared to previously published data (21--53%). As MS is more common in the early stages and decreases with COPD progression, the COPD patients admitted for exacerbation may be considered as having advanced COPD.
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